ALKERMES | ALKS - Marktkapitalisierung

Aktienkurs
33.31
Täglich Wechseln
-0.60 -1.77%
Monatlich
13.42%
Jährlich
19.65%
Q2 Prognose
32.32




Marktkapitalisierung Veränderung Datum
AbbVie USD 403.83B 5.2B 2025-12
Acadia Pharmaceuticals USD 4.52B 919M 2025-12
ALKERMES USD 4.62B 333M 2025-12
Amgen USD 176.25B 24.32B 2025-12
Biogen USD 25.82B 5.28B 2025-12
BioMarin Pharmaceutical USD 11.42B 1.02B 2025-12
Bristol-Myers Squibb USD 109.81B 18.01B 2025-12
Coherus Biosciences USD 172M 19M 2025-12
Eli Lilly USD 1.02T 293.84B 2025-12
Gilead Sciences USD 166.62B 14.34B 2026-04
Heron Therapeutics USD 238M 7M 2025-12
Ionis Pharmaceuticals USD 12.81B 2.39B 2025-12
J&J USD 561.65B 17.5B 2026-04
Malin Corporation EUR 142.92M 19.65M 2026-02
Merck USD 261.26B 51.62B 2025-12
Nektar Therapeutics USD 14.34B 13.48B 2026-04
Neurocrine Biosciences USD 14.14B 218M 2025-12
Otsuka Holdings JPY 4.82T 550.59B 2025-12
Ovoca Bio EUR 6.12M 4.93M 2026-04
Pfizer USD 141.57B 6.48B 2025-12
Regeneron Pharmaceuticals USD 81.12B 21.53B 2025-12
Vertex Pharmaceuticals USD 115.03B 14.61B 2025-12